$LPCN
Lipocine Inc. Stock $lpcn

$lpcn Overview Financials Valuation SEC Filings Company Website

2023 Q1 Form 10-K Financial Statement

#000149315223007178 Filed on March 10, 2023

Income Statement

Concept	2023 Q1	2022 Q4	2022
Revenue	$55.00K	$0.00	$500.0K
YoY Change		-100.0%	-96.9%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$1.287M	$890.3K	$4.062M
YoY Change	3.51%	-15.05%	-23.78%
% of Gross Profit
Research & Development	$3.106M	$1.670M	$8.557M
YoY Change	64.53%	-25.88%	11.63%
% of Gross Profit
Depreciation & Amortization	$4.820K	$2.570K	$9.500K
YoY Change	180.23%	576.32%	2400.0%
% of Gross Profit
Operating Expenses	$4.394M	$2.561M	$12.62M
YoY Change	40.3%	-22.44%	-2.89%
Operating Profit	-$4.339M		-$12.12M
YoY Change	38.54%		-485.29%
Interest Expense		$297.2K	$27.10K
YoY Change		-3192.2%	-119.99%
% of Operating Profit
Other Income/Expense, Net	$468.6K	$34.24K	$1.361M
YoY Change	-223.97%	-122.78%	282.54%
Pretax Income	-$3.870M	-$2.229M	-$10.76M
YoY Change	10.97%	-117.66%	1596.3%
Income Tax	$200.00	$480.00	$681.00
% Of Pretax Income
Net Earnings	-$3.870M	-$2.230M	-$10.76M
YoY Change	10.97%	-117.66%	1595.88%
Net Earnings / Revenue	-7036.78%		-2151.73%
Basic Earnings Per Share	-$0.04		-$0.12
Diluted Earnings Per Share	-$0.04	-$0.02	-$0.13
COMMON SHARES
Basic Shares Outstanding	88.51M shares	88.51M shares	88.46M shares
Diluted Shares Outstanding	88.51M shares		88.88M shares

Balance Sheet

Concept	2023 Q1	2022 Q4	2022
SHORT-TERM ASSETS
Cash & Short-Term Investments	$28.87M	$32.53M	$32.53M
YoY Change	-31.26%	-27.09%	-27.09%
Cash & Equivalents	$4.769M	$3.148M	$3.149M
Short-Term Investments	$24.10M	$29.38M	$29.38M
Other Short-Term Assets	$1.706M	$1.525M	$1.525M
YoY Change	23.82%	0.68%	0.68%
Inventory
Prepaid Expenses
Receivables	$39.06K	$80.43K	$80.43K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$30.61M	$34.14M	$34.14M
YoY Change	-29.62%	-26.4%	-26.4%
LONG-TERM ASSETS
Property, Plant & Equipment	$130.8K	$131.6K	$131.6K
YoY Change	304.99%	1725.09%	1725.1%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments		$0.00	$0.00
YoY Change		-100.0%	-100.0%
Other Assets	$23.75K	$23.75K	$23.75K
YoY Change	0.01%	0.01%	0.0%
Total Long-Term Assets	$3.407M	$3.408M	$3.408M
YoY Change	-17.02%	-44.16%	-44.16%
TOTAL ASSETS
Total Short-Term Assets	$30.61M	$34.14M	$34.14M
Total Long-Term Assets	$3.407M	$3.408M	$3.408M
Total Assets	$34.02M	$37.54M	$37.54M
YoY Change	-28.53%	-28.47%	-28.47%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$796.5K	$600.4K	$600.4K
YoY Change	69.5%	-53.43%	-53.43%
Accrued Expenses	$1.134M	$1.078M	$1.078M
YoY Change	-27.7%	-46.55%	-46.55%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due		$0.00	$0.00
YoY Change		-100.0%	-100.0%
Total Short-Term Liabilities	$1.930M	$1.678M	$1.678M
YoY Change	-45.17%	-70.12%	-70.12%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$131.7K	$229.9K	$229.9K
YoY Change	-92.13%	-82.26%	-82.26%
Total Long-Term Liabilities	$131.7K	$229.9K	$229.9K
YoY Change	-92.13%		-82.26%
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.930M	$1.678M	$1.678M
Total Long-Term Liabilities	$131.7K	$229.9K	$229.9K
Total Liabilities	$2.062M	$1.908M	$1.908M
YoY Change	-60.3%	-72.4%	-72.4%
SHAREHOLDERS EQUITY
Retained Earnings	-$187.3M	-$183.4M
YoY Change		6.23%
Common Stock	$8.852K	$8.852K
YoY Change		0.26%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$40.71K	$40.71K
YoY Change		0.0%
Treasury Stock Shares		5.710K shares
Shareholders Equity	$31.96M	$35.63M	$35.63M
YoY Change
Total Liabilities & Shareholders Equity	$34.02M	$37.54M	$37.54M
YoY Change	-28.53%	-28.47%	-28.47%

Cashflow Statement

Concept	2023 Q1	2022 Q4	2022
OPERATING ACTIVITIES
Net Income	-$3.870M	-$2.230M	-$10.76M
YoY Change	10.97%	-117.66%	1595.88%
Depreciation, Depletion And Amortization	$4.820K	$2.570K	$9.500K
YoY Change	180.23%	576.32%	2400.0%
Cash From Operating Activities	-$3.928M	-$1.839M	-$11.97M
YoY Change	1.1%	-120.44%	171.32%
INVESTING ACTIVITIES
Capital Expenditures	$4.000K	$96.73K	$133.8K
YoY Change	-114.93%	-1374.44%	-1863.25%
Acquisitions
YoY Change
Other Investing Activities	$5.559M	$2.693M	$14.43M
YoY Change	-24.08%	-127.72%	-132.96%
Cash From Investing Activities	$5.555M	$2.596M	$14.29M
YoY Change	-23.86%	-126.7%	-132.65%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$0.00
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-$6.016K	-5.900K	-$2.127M
YoY Change	-99.04%	-99.3%	-107.9%
NET CHANGE
Cash From Operating Activities	-$3.928M	-1.839M	-$11.97M
Cash From Investing Activities	$5.555M	2.596M	$14.29M
Cash From Financing Activities	-$6.016K	-5.900K	-$2.127M
Net Change In Cash	$1.621M	751.5K	$197.9K
YoY Change	-41.76%	-147.97%	-100.93%
FREE CASH FLOW
Cash From Operating Activities	-$3.928M	-$1.839M	-$11.97M
Capital Expenditures	$4.000K	$96.73K	$133.8K
Free Cash Flow	-$3.932M	-$1.936M	-$12.10M
YoY Change	1.9%	-121.5%	174.83%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0001535955
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2021Q4	us-gaap	Contract With Customer Asset Net Current ContractWithCustomerAssetNetCurrent		usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent		usd
CY2022Q4	us-gaap	Debt Current DebtCurrent		usd
CY2022Q4	us-gaap	Litigation Reserve Current LitigationReserveCurrent		usd
CY2022Q4	us-gaap	Litigation Reserve Noncurrent LitigationReserveNoncurrent		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2021	lpcn	Gain On Related To Litigation Settlement Liability GainOnRelatedToLitigationSettlementLiability		usd
CY2021	lpcn	End Of Loan Payment EndOfLoanPayment		usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock		usd
CY2022	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises		usd
CY2022	lpcn	Settlement Of Warrant Liability On Warrant Exercises SettlementOfWarrantLiabilityOnWarrantExercises		usd
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax		usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost		usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue		usd
CY2022	us-gaap	Federal Income Tax Expense Benefit Continuing Operations FederalIncomeTaxExpenseBenefitContinuingOperations		usd
CY2021	us-gaap	Federal Income Tax Expense Benefit Continuing Operations FederalIncomeTaxExpenseBenefitContinuingOperations		usd
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit		usd
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit		usd
CY2022	us-gaap	Income Tax Reconciliation Other Reconciling Items IncomeTaxReconciliationOtherReconcilingItems		usd
CY2021Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment		usd
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		usd
CY2021Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		usd
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits		usd
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits		usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits		usd
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits		usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue		usd
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1		usd
CY2022	dei	Document Type DocumentType	10-K
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-12-31
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Entity File Number EntityFileNumber	001-36357
CY2022	dei	Entity Registrant Name EntityRegistrantName	LIPOCINE INC.
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2022	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	99-0370688
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	675 Arapeen Drive
CY2022	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 202
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	Salt Lake City
CY2022	dei	Entity Address State Or Province EntityAddressStateOrProvince	UT
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	84108
CY2022	dei	City Area Code CityAreaCode	801
CY2022	dei	Local Phone Number LocalPhoneNumber	994-7383
CY2022	dei	Security12b Title Security12bTitle	Common Stock, par value $0.0001 per share
CY2022	dei	Trading Symbol TradingSymbol	LPCN
CY2022	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022	dei	Entity Small Business EntitySmallBusiness	true
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Public Float EntityPublicFloat	69200000	usd
CY2023Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	88510791	shares
CY2022	dei	Auditor Name AuditorName	Tanner LLC
CY2022	dei	Auditor Location AuditorLocation	Salt Lake City, Utah
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3148496	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2950552	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	29381410	usd
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	41667405	usd
CY2022Q4	us-gaap	Interest Receivable Current InterestReceivableCurrent	80427	usd
CY2021Q4	us-gaap	Interest Receivable Current InterestReceivableCurrent	247253	usd
CY2022Q4	us-gaap	Contract With Customer Asset Net Current ContractWithCustomerAssetNetCurrent	579428	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	945319	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1514465	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	34135080	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	46379675	usd
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	2021800	usd
CY2022Q4	us-gaap	Contract With Customer Asset Net Noncurrent ContractWithCustomerAssetNetNoncurrent	3252500	usd
CY2021Q4	us-gaap	Contract With Customer Asset Net Noncurrent ContractWithCustomerAssetNetNoncurrent	4050000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1153530	usd
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1144077	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	131589	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	7211	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	23753	usd
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	23753	usd
CY2022Q4	us-gaap	Assets Assets	37542922	usd
CY2021Q4	us-gaap	Assets Assets	52482439	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	600388	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1289342	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1077738	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1016458	usd
CY2021Q4	us-gaap	Debt Current DebtCurrent	2310825	usd
CY2021Q4	us-gaap	Litigation Reserve Current LitigationReserveCurrent	1000000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1678126	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	5616625	usd
CY2022Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	229856	usd
CY2021Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	795796	usd
CY2021Q4	us-gaap	Litigation Reserve Noncurrent LitigationReserveNoncurrent	500000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	1907982	usd
CY2021Q4	us-gaap	Liabilities Liabilities	6912421	usd
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	88516501	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	88296360	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	88510791	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	88290650	shares
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	8852	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	8830	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	219112164	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	218286323	usd
CY2022Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	5710	shares
CY2021Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	5710	shares
CY2022Q4	us-gaap	Treasury Stock Value TreasuryStockValue	40712	usd
CY2021Q4	us-gaap	Treasury Stock Value TreasuryStockValue	40712	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-20321	usd
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-18016	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-183425043	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-172666407	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	35634940	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	45570018	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	37542922	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	52482439	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	500000	usd
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	16140838	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	8556888	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	7665559	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4062487	usd
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5329776	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	12619375	usd
CY2021	us-gaap	Operating Expenses OperatingExpenses	12995335	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-12119375	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	3145503	usd
CY2022	us-gaap	Investment Income Interest InvestmentIncomeInterest	572578	usd
CY2021	us-gaap	Investment Income Interest InvestmentIncomeInterest	67700	usd
CY2022	us-gaap	Interest Expense InterestExpense	27098	usd
CY2021	us-gaap	Interest Expense InterestExpense	203292	usd
CY2022	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	565940	usd
CY2021	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	355890	usd
CY2022	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	250000	usd
CY2021	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	-4000000	usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1361420	usd
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-3779702	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-10757955	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-634199	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	681	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	200	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-10758636	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-634399	usd
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.12
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.01
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	88457243	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	86934618	shares
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.13
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.01
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	88875946	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	87623452	shares
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-10758636	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-634399	usd
CY2022	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-2305	usd
CY2021	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-18016	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-10760941	usd
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-652415	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	15341919	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-634399	usd
CY2021	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-18016	usd
CY2021	lpcn	Common Stock Sold Through Equity Offering CommonStockSoldThroughEquityOffering	26840457	usd
CY2021	lpcn	Stock Issued During Period Value Warrants Exercises StockIssuedDuringPeriodValueWarrantsExercises	5000	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	603946	usd
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	6693	usd
CY2021	lpcn	Adjustments To Additional Paid In Capital Settlement Of Warrant Liability On Warrant Exercises AdjustmentsToAdditionalPaidInCapitalSettlementOfWarrantLiabilityOnWarrantExercises	18365	usd
CY2021	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	3406053	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	45570018	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-10758636	usd
CY2022	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-2305	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	636140	usd
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	211423	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	21700	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	35634940	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-10758636	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-634399	usd
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	9453	usd
CY2021	us-gaap	Depreciation And Amortization DepreciationAndAmortization	380	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	636140	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	603946	usd
CY2022	us-gaap	Accretion Expense AccretionExpense	5842	usd
CY2021	us-gaap	Accretion Expense AccretionExpense	53750	usd
CY2022	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-565940	usd
CY2021	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-355890	usd
CY2022	lpcn	Gain On Related To Litigation Settlement Liability GainOnRelatedToLitigationSettlementLiability	250000	usd
CY2022	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	122048	usd
CY2021	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-515577	usd
CY2022	us-gaap	Increase Decrease In Accrued Interest Receivable Net IncreaseDecreaseInAccruedInterestReceivableNet	-166826	usd
CY2021	us-gaap	Increase Decrease In Accrued Interest Receivable Net IncreaseDecreaseInAccruedInterestReceivableNet	246862	usd
CY2022	us-gaap	Increase Decrease In Contract With Customer Asset IncreaseDecreaseInContractWithCustomerAsset	-218072	usd
CY2021	us-gaap	Increase Decrease In Contract With Customer Asset IncreaseDecreaseInContractWithCustomerAsset	4050000	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-569146	usd
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	853207	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-688954	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-307878	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	61280	usd
CY2021	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-636720	usd
CY2022	lpcn	Litigation Settlement Liability LitigationSettlementLiability	-1250000	usd
CY2021	lpcn	Litigation Settlement Liability LitigationSettlementLiability	1500000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-11968819	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4411303	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	133831	usd
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	7591	usd
CY2022	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	45074462	usd
CY2021	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	48422806	usd
CY2022	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	59502000	usd
CY2021	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	4650000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	14293707	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-43780397	usd
CY2022	us-gaap	Repayments Of Debt RepaymentsOfDebt	1666667	usd
CY2021	us-gaap	Repayments Of Debt RepaymentsOfDebt	3333333	usd
CY2022	lpcn	End Of Loan Payment EndOfLoanPayment	650000	usd
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	211423	usd
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	6693	usd
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	26840457	usd
CY2021	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	5000	usd
CY2022	lpcn	Proceeds From Repayments Of Costs Associated With Offering ProceedsFromRepaymentsOfCostsAssociatedWithOffering	-21700	usd
CY2021	lpcn	Proceeds From Repayments Of Costs Associated With Offering ProceedsFromRepaymentsOfCostsAssociatedWithOffering	3406053	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-2126944	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	26924870	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	197944	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-21266830	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	2950552	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	24217382	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	3148496	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	2950552	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	21256	usd
CY2021	us-gaap	Interest Paid Net InterestPaidNet	149543	usd
CY2022	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	200	usd
CY2021	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	200	usd
CY2021	lpcn	Settlement Of Warrant Liability On Warrant Exercises SettlementOfWarrantLiabilityOnWarrantExercises	18365	usd
CY2022	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-2305	usd
CY2021	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-18016	usd
CY2022	lpcn	Accrued Final Payment Charge On Debt AccruedFinalPaymentChargeOnDebt	5842	usd
CY2021	lpcn	Accrued Final Payment Charge On Debt AccruedFinalPaymentChargeOnDebt	53750	usd
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_84B_eus-gaap--UseOfEstimates_zMJO3lBI7zd2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>(a)</i></b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_866_zhqlI9zcb678">Use of Estimates</span> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 48.95pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with U.S. generally accepted accounting principles (“US GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant items subject to such estimates and assumptions include those related to the timing and amount of revenue recognized from licensing agreements, stock-based compensation; income tax uncertainties; the fair value of the warrant liability and the useful lives of property and equipment.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 48.95pt; text-indent: -24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p>
CY2022Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	3100000	usd
CY2021Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	3000000.0	usd
CY2022	us-gaap	Revenues Revenues	500000	usd
CY2021	us-gaap	Revenues Revenues	16140838	usd
CY2021	lpcn	Dilutive Common Stock Warrants Attributable To Common Stock Shares DilutiveCommonStockWarrantsAttributableToCommonStockShares	688834	shares
CY2022	lpcn	Weighted Average Effect Of Diluted Shares Outstanding WeightedAverageEffectOfDilutedSharesOutstanding	88875946	shares
CY2021	lpcn	Weighted Average Effect Of Diluted Shares Outstanding WeightedAverageEffectOfDilutedSharesOutstanding	87623452	shares
CY2022	us-gaap	Income Tax Examination Likelihood Of Unfavorable Settlement IncomeTaxExaminationLikelihoodOfUnfavorableSettlement	greater than 50 percent
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	636000	usd
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	604000	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	636140	usd
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	603946	usd
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.13
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.01
CY2022Q4	us-gaap	Available For Sale Securities Debt Maturities Single Maturity Date Amortized Cost Basis AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis	29401731	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Maturities Single Maturity Date AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate	29381410	usd
CY2022	us-gaap	Proceeds From Sale Of Held To Maturity Securities ProceedsFromSaleOfHeldToMaturitySecurities	0	usd
CY2021	us-gaap	Proceeds From Sale Of Held To Maturity Securities ProceedsFromSaleOfHeldToMaturitySecurities	0	usd
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y9M25D
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y9M29D
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0306	pure
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0104	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.9931	pure
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.0218	pure
CY2022Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	1000000.0	usd
CY2022	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y10M24D
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.53
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.97
CY2022Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	32075844	usd
CY2022Q4	us-gaap	Fair Value Net Asset Liability FairValueNetAssetLiability	32305700	usd
CY2021Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	45778956	usd
CY2021Q4	us-gaap	Fair Value Net Asset Liability FairValueNetAssetLiability	46574752	usd
CY2021	lpcn	Dilutive Common Stock Warrants Attributable To Common Stock Shares DilutiveCommonStockWarrantsAttributableToCommonStockShares	688834	shares
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-10758636	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-634399	usd
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	88457243	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	86934618	shares
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.12
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.01
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-10758636	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-634399	usd
CY2022	lpcn	Dilutive Common Stock Warrants Attributable To Common Stock DilutiveCommonStockWarrantsAttributableToCommonStock	565940	usd
CY2021	lpcn	Dilutive Common Stock Warrants Attributable To Common Stock DilutiveCommonStockWarrantsAttributableToCommonStock	355890	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-11324576	usd
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-990289	usd
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	88457243	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	86934618	shares
CY2022	lpcn	Dilutive Common Stock Warrants Attributable To Common Stock Shares DilutiveCommonStockWarrantsAttributableToCommonStockShares	418703	shares
CY2022Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	29401731	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	4651	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	24972	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	29381410	usd
CY2021Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	43707221	usd
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	18016	usd
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	43689205	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost	29401731	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	29381410	usd
CY2022	us-gaap	Debt And Equity Securities Realized Gain Loss DebtAndEquitySecuritiesRealizedGainLoss	0	usd
CY2021	us-gaap	Debt And Equity Securities Realized Gain Loss DebtAndEquitySecuritiesRealizedGainLoss	0	usd
CY2022	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	59500000	usd
CY2021	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	4700000	usd
CY2022	us-gaap	Other Than Temporary Impairment Credit Losses Recognized In Earnings Additions No Previous Impairment OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsAdditionsNoPreviousImpairment	0	usd
CY2021	us-gaap	Other Than Temporary Impairment Credit Losses Recognized In Earnings Additions No Previous Impairment OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsAdditionsNoPreviousImpairment	0	usd
CY2022	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	5600000	usd
CY2021	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	4900000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1285119	usd
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1151288	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1153530	usd
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1144077	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	131589	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	7211	usd
CY2022	us-gaap	Depreciation Depreciation	9500	usd
CY2021	us-gaap	Depreciation Depreciation	400	usd
CY2022Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	1997787	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Other DeferredTaxAssetsTaxCreditCarryforwardsOther	69273	usd
CY2022	us-gaap	State And Local Income Tax Expense Benefit Continuing Operations StateAndLocalIncomeTaxExpenseBenefitContinuingOperations	681	usd
CY2021	us-gaap	State And Local Income Tax Expense Benefit Continuing Operations StateAndLocalIncomeTaxExpenseBenefitContinuingOperations	200	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	681	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	200	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	681	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	200	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2022	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-2259272	usd
CY2021	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-133182	usd
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	2529547	usd
CY2021	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	476431	usd
CY2022	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	538	usd
CY2021	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	158	usd
CY2022	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	314186	usd
CY2021	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	97697	usd
CY2022	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	422495	usd
CY2021	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	352163	usd
CY2022	lpcn	Income Tax Reconciliation Orphan Drug Tax Credits IncomeTaxReconciliationOrphanDrugTaxCredits	42976	usd
CY2021	lpcn	Income Tax Reconciliation Orphan Drug Tax Credits IncomeTaxReconciliationOrphanDrugTaxCredits	14025	usd
CY2022	lpcn	Effective Income Tax Rate Reconciliation Nondeductible Expense Warrant Liability Amount EffectiveIncomeTaxRateReconciliationNondeductibleExpenseWarrantLiabilityAmount	-118847	usd
CY2021	lpcn	Effective Income Tax Rate Reconciliation Nondeductible Expense Warrant Liability Amount EffectiveIncomeTaxRateReconciliationNondeductibleExpenseWarrantLiabilityAmount	-74737	usd
CY2021	us-gaap	Income Tax Reconciliation Other Reconciling Items IncomeTaxReconciliationOtherReconcilingItems	21	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	681	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	200	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	1428167	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	1687480	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	35595940	usd
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	34759890	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits	44602	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits	56009	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	5491805	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	4935609	usd
CY2022Q4	lpcn	Deferred Tax Assets Orphan Drug Tax Credit DeferredTaxAssetsOrphanDrugTaxCredit	1240982	usd
CY2021Q4	lpcn	Deferred Tax Assets Orphan Drug Tax Credit DeferredTaxAssetsOrphanDrugTaxCredit	1186582	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Other DeferredTaxAssetsTaxCreditCarryforwardsOther	394636	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	45868556	usd
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	43020206	usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	45868556	usd
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	43020206	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	9052	usd
CY2021Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	1871	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	9052	usd
CY2021Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	1871	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	9052	usd
CY2021Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	1871	usd
CY2022Q4	lpcn	Deferred Tax Assetdeferred Tax Liability DeferredTaxAssetdeferredTaxLiability	45859504	usd
CY2021Q4	lpcn	Deferred Tax Assetdeferred Tax Liability DeferredTaxAssetdeferredTaxLiability	43018335	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	45859504	usd
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	43018335	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	45900000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	43000000.0	usd
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	2900000	usd
CY2021	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	563000	usd
CY2022	lpcn	Operating Loss Carry Forwards Limitations On Use Amount OperatingLossCarryForwardsLimitationsOnUseAmount	1100000	usd
CY2022	lpcn	Operating Loss Carry Forwards Preownership Change Amount OperatingLossCarryForwardsPreownershipChangeAmount	20200000	usd
CY2022	lpcn	Operating Loss Forgive Pre Ownership Change Amount OperatingLossForgivePreOwnershipChangeAmount	5500000	usd
CY2022	lpcn	Tax Credit Carryforward Pre Ownership Change Amount TaxCreditCarryforwardPreOwnershipChangeAmount	1200000	usd
CY2022Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	140000000.0	usd
CY2022Q4	us-gaap	Tax Credit Carryforward Amount TaxCreditCarryforwardAmount	3900000	usd
CY2022	lpcn	Operating Loss Carry Forwards Expiration Date1 OperatingLossCarryForwardsExpirationDate1	Approximately $24.4 million of the NOL will expire between 2023 and 2033 and $70.8 million of the NOL will expire 2034 through 2037. Pursuant to the Tax Cuts and Jobs Act of 2017, NOL’s generated in 2018 and subsequent years have an unlimited carryforward therefore the 2022, 2020, 2019 and 2018 NOL of $44.8 million can be carried forward indefinitely. The research and development credits will begin to expire in 2033 through 2041.
CY2021Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	795796	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	355070	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	59559	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	414629	usd
CY2022	us-gaap	Operating Lease Expense OperatingLeaseExpense	341000	usd
CY2021	us-gaap	Operating Lease Expense OperatingLeaseExpense	330000	usd
CY2015Q4	lpcn	Class Of Warrants Or Right Redemption Price Of Warrants Or Rights ClassOfWarrantsOrRightRedemptionPriceOfWarrantsOrRights	63.96
CY2022	lpcn	Class Of Warrants Or Right Redemption Price Of Warrants Or Rights ClassOfWarrantsOrRightRedemptionPriceOfWarrantsOrRights	0.001
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	4713862	shares
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y6M
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.29
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	2909529	shares
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P4Y9M10D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	3.19
CY2022	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-565940	usd
CY2022Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	229856	usd
CY2022	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent Of Match DefinedContributionPlanEmployerMatchingContributionPercentOfMatch	1	pure
CY2022	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	94000	usd
CY2021	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	81000	usd
CY2019Q4	us-gaap	Payments For Legal Settlements PaymentsForLegalSettlements	1250000	usd
CY2022	dei	Auditor Firm AuditorFirmId	270

Files In Submission

Name	View Source	Status
FilingSummary.xml	Edgar Link	unprocessable
0001493152-23-007178-index-headers.html	Edgar Link	pending
0001493152-23-007178-index.html	Edgar Link	pending
0001493152-23-007178.txt	Edgar Link	pending
0001493152-23-007178-xbrl.zip	Edgar Link	pending
ex21-1.htm	Edgar Link	pending
ex23-1.htm	Edgar Link	pending
ex3-6.htm	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-k.htm	Edgar Link	pending
form10-k_001.jpg	Edgar Link	pending
form10-k_002.jpg	Edgar Link	pending
lpcn-20221231.xsd	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
lpcn-20221231_cal.xml	Edgar Link	unprocessable
lpcn-20221231_def.xml	Edgar Link	unprocessable
lpcn-20221231_lab.xml	Edgar Link	unprocessable
lpcn-20221231_pre.xml	Edgar Link	unprocessable
form10-k_htm.xml	Edgar Link	completed
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$LPCN
Lipocine Inc. Stock $lpcn

2023 Q1 Form 10-K Financial Statement

#000149315223007178 Filed on March 10, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LPCN Lipocine Inc. Stock $lpcn

2023 Q1 Form 10-K Financial Statement

#000149315223007178 Filed on March 10, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LPCN
Lipocine Inc. Stock $lpcn